One Shot to Rule Them All: The Vaccine That Replaces Two

Why First-Mover Status Is a Big Deal

Moderna desperately needed this win. The company's COVID vaccine revenue peaked during the pandemic and has been sliding ever since. In 2025, total revenue came in around $1.94 billion; a far cry from the pandemic highs. The company is still burning cash, with projected operating expenses of about $4.9 billion in 2026.

The math only works if Moderna can turn its mRNA platform into something bigger than a one-trick pony. That's where the combo vaccine fits in.

Analysts at Jefferies estimate the total addressable market for a flu-COVID combination vaccine in the EU alone at roughly $1.7 billion. They project Moderna's combined U.S. flu and combo revenues could reach about $750 million by 2030. Those aren't blowout numbers, but they represent exactly the kind of recurring, seasonal revenue that transforms a company's financial story.

Moderna is targeting up to 10% revenue growth in 2026 versus 2025, with mCOMBRIAX as one of the key drivers alongside its standalone flu vaccine (mRNA-1010, awaiting a U.S. FDA decision by August 5, 2026) and its RSV vaccine mRESVIA. The goal: reach cash breakeven by 2028.

The Competition Is Closer Than You Think

Moderna may have crossed the finish line first, but the runners-up are close.

Pfizer and BioNTech have their own mRNA-based flu-COVID combo in Phase 3. The problem? Their trial missed one of two primary endpoints, specifically the influenza B component. That's like acing half the final exam and bombing the other half. It could mean reformulation, additional trials, and a delayed timeline.

Sanofi and Novavax are taking a different approach entirely. Their combo pairs Novavax's protein-based COVID antigen (not mRNA) with Sanofi's established flu vaccine backbone. Early Phase 1/2 data showed promise, and for the segment of patients and health systems that prefer non-mRNA options, this partnership could be a real contender.

There's also a quirky subplot: Pfizer licensed Novavax's Matrix-M adjuvant in early 2026 for use in two undisclosed disease areas, paying $30 million upfront with up to $500 million in milestones. So Novavax is simultaneously competing with and supplying technology to one of its biggest rivals. The vaccine business, apparently, is complicated.

The Bigger Picture: mRNA Grows Up

Beyond the commercial horse race, this approval validates something that was theoretical until now. The mRNA platform can protect against multiple unrelated pathogens in a single shot.

The European Medicines Agency is already building the regulatory scaffolding for this future. New European Pharmacopoeia standards for mRNA-LNP vaccines are rolling out in 2025, and a formal "platform technology master file" system (already used for veterinary vaccines) is expected to get a legal definition for human medicines soon. That framework would let companies reuse their platform data across multiple vaccine applications, dramatically cutting the paperwork and time needed for each new combo product.

Moderna has 41 mRNA candidates in its pipeline. Beyond respiratory vaccines, there are programs in oncology, rare diseases, and latent viruses like CMV and EBV. The company expects up to 10 product approvals over the next three years. If the platform approach works as advertised, each new approval gets a little easier, a little cheaper, and a little faster than the last.

What Comes Next

The EU approval is a milestone, but it's not the whole story. Rollout will happen country by country, with each nation making its own pricing and reimbursement decisions. The bigger question mark hangs over the United States, where Moderna is still awaiting FDA guidance on refiling its combo vaccine application after earlier regulatory setbacks. Without the U.S. market (the world's largest for vaccines), mCOMBRIAX's commercial potential stays capped.

Still, the significance is hard to overstate. For decades, the dream of simplifying seasonal vaccination into fewer shots seemed perpetually five years away. Moderna just made it real for tens of millions of European adults.

One arm. One shot. Two diseases covered. Sometimes the best innovation isn't a new drug; it's making an existing routine less annoying.